The Pan American Health Organization (PAHO) announces a new agreement with Gilead Sciences to make lenacapavir accessible in 14 countries in Latin America and the Caribbean. This preventive medication, administered twice a year, aims to reduce new HIV infections in the region. PAHO emphasizes the importance of strategic partnerships to improve access to public health innovations and strengthen local production capacities.